GPC3 and hepatocellular carcinoma: In the follow‐up of eight HCC patients (including those treated with PD‐L1 therapy, surgical resection, and radiotherapy), we observed that the mRNA and protein levels of EpCAM and GPC‐3 shifted to the left, particularly in patients treated with PD‐L1 therapy (HCC29, HCC35, and HCC48), and the 2D distribution of EpCAM shifted significantly to the left.